Anti-IL17/ IL17A/ CTLA-8 functional antibody

Anti-IL17/ IL17A/ CTLA-8 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to IL17/IL17A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T22095-Ab-1/ GM-Tg-hg-T22095-Ab-2Anti-Human IL17/IL17A monoclonal antibodyHuman
GM-Tg-rg-T22095-Ab-1/ GM-Tg-rg-T22095-Ab-2Anti-Rat IL17/IL17A monoclonal antibodyRat
GM-Tg-mg-T22095-Ab-1/ GM-Tg-mg-T22095-Ab-2Anti-Mouse IL17/IL17A monoclonal antibodyMouse
GM-Tg-cynog-T22095-Ab-1/ GM-Tg-cynog-T22095-Ab-2Anti-Cynomolgus/ Rhesus macaque IL17/IL17A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T22095-Ab-1/ GM-Tg-felg-T22095-Ab-2Anti-Feline IL17/IL17A monoclonal antibodyFeline
GM-Tg-cang-T22095-Ab-1/ GM-Tg-cang-T22095-Ab-2Anti-Canine IL17/IL17A monoclonal antibodyCanine
GM-Tg-bovg-T22095-Ab-1/ GM-Tg-bovg-T22095-Ab-2Anti-Bovine IL17/IL17A monoclonal antibodyBovine
GM-Tg-equg-T22095-Ab-1/ GM-Tg-equg-T22095-Ab-2Anti-Equine IL17/IL17A monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T22095-Ab-1/ GM-Tg-hg-T22095-Ab-2; GM-Tg-rg-T22095-Ab-1/ GM-Tg-rg-T22095-Ab-2;
GM-Tg-mg-T22095-Ab-1/ GM-Tg-mg-T22095-Ab-2; GM-Tg-cynog-T22095-Ab-1/ GM-Tg-cynog-T22095-Ab-2;
GM-Tg-felg-T22095-Ab-1/ GM-Tg-felg-T22095-Ab-2; GM-Tg-cang-T22095-Ab-1/ GM-Tg-cang-T22095-Ab-2;
GM-Tg-bovg-T22095-Ab-1/ GM-Tg-bovg-T22095-Ab-2; GM-Tg-equg-T22095-Ab-1/ GM-Tg-equg-T22095-Ab-2
Products NameAnti-IL17/IL17A monoclonal antibody
Formatmab
Target NameIL17
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-IL17 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-478Pre-Made Remtolumab biosimilar, Bispecific Dual Variable Domain IG: Anti-IL17A/IL17;TNFA/TNF therapeutic antibody
    BiosimilarGMP-Bios-ab-438Pre-Made Perakizumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
    BiosimilarGMP-Bios-ab-374Pre-Made Netakimab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
    BiosimilarGMP-Bios-ab-286Pre-Made Ixekizumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
    BiosimilarGMP-Bios-ab-671Pre-Made Gumokimab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
    BiosimilarGMP-Bios-ab-070Pre-Made Bimekizumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
    BiosimilarGMP-Bios-ab-568Pre-Made Tibulizumab biosimilar, Bispecific Mixed mAb and scFv, Anti-TNFSF13B;IL17A/IL17 Antibody: Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4;CTLA-8/CTLA8A therapeutic antibody
    BiosimilarGMP-Bios-ab-710Pre-Made Xeligekimab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
    BiosimilarGMP-Bios-ab-510Pre-Made Secukinumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
    BiosimilarGMP-Bios-ab-012Pre-Made Afasevikumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
    BiosimilarGMP-Bios-ab-633Pre-Made Vunakizumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
    BiosimilarGMP-Bios-INN-996Pre-Made Sonelokimab Biosimilar, Bispecific, Anti-ALB;IL17A/IL17;IL17F Antibody: Anti-FDAHT/HSA/PRO0883/PRO0903/PRO1341;CTLA-8/CTLA8/IL-17A/ILA17;CANDF6/ML-1/ML1 therapeutic antibody
    Target AntigenGM-Tg-g-T22095-Ag-1Recombinant multi-species IL17/ IL17A/ CTLA-8 protein
    CytokineGM-Tg-g-T22095-Ag-1Marmoset interleukin IL17 (IL17A) protein
    ORF Viral VectorpGMAP000304human IL17A Adenovirus plasmid
    ORF Viral VectorpGMLP000168human IL17A Lentivirus plasmid
    ORF Viral VectorvGMAP000304human IL17A Adenovirus particle
    ORF Viral VectorvGMLP000168human IL17A Lentivirus particle
    ORF Viral VectorpGMLPm000114mouse Il17a Lentivirus plasmid
    ORF Viral VectorvGMLPm000114mouse Il17a Lentivirus particle


    Target information

    Target IDGM-T22095
    Target NameIL17
    Gene ID3605,16171,301289,708123,481837,101095339,282863,100034142
    Gene Symbol and SynonymsCTLA-8,CTLA8,IL-17,IL-17A,IL17,IL17A,ILA17
    Uniprot AccessionQ16552,Q61453,Q687Y7
    Uniprot Entry NameIL17_HUMAN,IL17_RAT,IL17_BOVIN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseCancer
    Gene EnsemblENSG00000112115
    Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)

    The target: IL17, gene name: IL17A, also named as CTLA-8, CTLA8, IL-17, IL-17A, IL17. This gene is a member of the IL-17 receptor family which includes five members (IL-17RA-E) and the encoded protein is a proinflammatory cytokine produced by activated T cells. IL-17A-mediated downstream pathways induce the production of inflammatory molecules, chemokines, antimicrobial peptides, and remodeling proteins. The encoded protein elicits crucial impacts on host defense, cell trafficking, immune modulation, and tissue repair, with a key role in the induction of innate immune defenses. This cytokine stimulates non-hematopoietic cells and promotes chemokine production thereby attracting myeloid cells to inflammatory sites. This cytokine also regulates the activities of NF-kappaB and mitogen-activated protein kinases and can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). IL-17A plays a pivotal role in various infectious diseases, inflammatory and autoimmune disorders, and cancer. High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The lung damage induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is to a large extent, a result of the inflammatory response promoted by cytokines such as IL17A. [provided by RefSeq, Sep 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.